Probi AB (PROB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Region:Europe

Author(s):

Product Code:GDPH82167D

Download Sample Report download
Buy the Full ReportStarting from $250
Published on

November 2018

Total pages

45

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $250

About the Report

About the Report

Summary

Probi AB (Probi) is a biotechnology company develops, produces and markets probiotics. The company offers licenses for its technology and sells finished products in bulk. It focuses on products for the improvement of gastrointestinal health and immune system. It distributes its products to leading food, health-product and pharmaceutical companies in the functional food and consumer healthcare segments. Probi markets its products through four different platforms: Probi Premium, Probi Select, Probi LiveBac and Probi Bio-tract. The company has operational presence in Sweden, Rest of Europe, North America and Rest of world. Probi is headquartered in Lund, Sweden.

Probi AB (PROB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Products

Probi AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Probi AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Probi AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Probi AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Probi AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Probi AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Probi AB, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Probi Enters into Research Agreement with Wageningen University 11

Probi Enters into Co-Marketing Agreement with Pharmavite 12

Probi Enters Into Distribution Agreement With Dongkook Pharma 13

Probi Enters Into Agreement With BiO-LiFE Marketing For Probiotic Product 14

Symrise Enters Into R&D Agreement With Probi For Probiotic Products 15

Probi Enters Into Co-Marketing Agreement With Vifor Pharma 16

Probi Enters Into Distribution Agreement With Alvogen 17

USV Enters Into Distribution Agreement With Probi For Vibact IBS 18

Licensing Agreements 19

Ipsen Enters into Licensing Agreement with Probi 19

Acquisition 20

Symrise Completes Acquisition Of Additional 3.53% Stake In Probi 20

Probi AB-Key Competitors 21

Probi AB-Key Employees 22

Probi AB-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Financial Announcements 24

Aug 13, 2018: Q2 2018: Regained business momentum and strong margin improvement 24

Oct 25, 2017: Probi: Interim report Q1-Q3 2017 25

May 04, 2017: Probi continues on its successful growth path 29

Jan 10, 2017: Probi-Strong Growth in net Sales and Operating Profit in the Fourth Quarter 32

Corporate Communications 33

Oct 01, 2018: Probi names Tom Ronnlund as new CEO 33

Jul 19, 2018: Probi announces resignation of Jorn Andreas as CFO 34

Mar 14, 2018: Probi Appoints Ole Sogaard Andersen As Interim CEO 35

Feb 14, 2017: Probi appoints Jorn Andreas as new CFO 36

Government and Public Interest 37

Sep 11, 2017: New clinical study shows that Probi's probiotics support the immune system and may delay the onset of gluten intolerance in children 37

Product News 38

Feb 06, 2018: Probi's largest clinical trial confirms the immune enhancing impact of Probi Defendum and sheds new light on the mechanism 38

Other Significant Developments 39

Apr 11, 2018: Probi enters the bone health area-a new area for probiotics 39

Jan 25, 2018: Probi: Q4-2017 Year-End Report 40

Appendix 45

Methodology 45

About GlobalData 45

Contact Us 45

Disclaimer 45


List of Figure

List of Figures

Probi AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Probi AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Probi AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Probi AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Probi AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Probi AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Probi AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Probi AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List of Table

List of Tables

Probi AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Probi AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Probi AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Probi AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Probi AB, Deals By Therapy Area, 2012 to YTD 2018 9

Probi AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Probi Enters into Research Agreement with Wageningen University 11

Probi Enters into Co-Marketing Agreement with Pharmavite 12

Probi Enters Into Distribution Agreement With Dongkook Pharma 13

Probi Enters Into Agreement With BiO-LiFE Marketing For Probiotic Product 14

Symrise Enters Into R&D Agreement With Probi For Probiotic Products 15

Probi Enters Into Co-Marketing Agreement With Vifor Pharma 16

Probi Enters Into Distribution Agreement With Alvogen 17

USV Enters Into Distribution Agreement With Probi For Vibact IBS 18

Ipsen Enters into Licensing Agreement with Probi 19

Symrise Completes Acquisition Of Additional 3.53% Stake In Probi 20

Probi AB, Key Competitors 21

Probi AB, Key Employees 22

Probi AB, Subsidiaries 23

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022